[
    [
        {
            "time": "",
            "original_text": "公司具备完备的冷链物流配送服务体系和专业能力，冷链物流配送业务处于全国领先水平",
            "features": {
                "keywords": [
                    "冷链物流",
                    "服务体系",
                    "领先水平"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "物流",
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司具备完备的冷链物流配送服务体系和专业能力，冷链物流配送业务处于全国领先水平",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "公司目前暂无在国内新建Ellansé伊妍仕生产线的计划",
            "features": {
                "keywords": [
                    "Ellansé伊妍仕",
                    "生产线",
                    "计划"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司目前暂无在国内新建Ellansé伊妍仕生产线的计划",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "公司医美产品Ellansé伊妍仕不存在与王力宏合作代言关系",
            "features": {
                "keywords": [
                    "Ellansé伊妍仕",
                    "王力宏",
                    "代言"
                ],
                "sentiment_score": -0.1,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司医美产品Ellansé伊妍仕不存在与王力宏合作代言关系",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "原研西格列汀化合物在我国的专利将于2022年到期",
            "features": {
                "keywords": [
                    "西格列汀",
                    "专利",
                    "到期"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "原研西格列汀化合物在我国的专利将于2022年到期",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "公司西格列汀二甲双胍片将于明年原研专利到期后正式上市销售",
            "features": {
                "keywords": [
                    "西格列汀二甲双胍片",
                    "专利到期",
                    "上市销售"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "公司西格列汀二甲双胍片将于明年原研专利到期后正式上市销售",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "Ellansé伊妍仕自上市后受到市场广泛关注及欢迎，医美机构订单踊跃，客户使用反馈良好",
            "features": {
                "keywords": [
                    "Ellansé伊妍仕",
                    "市场关注",
                    "订单踊跃",
                    "反馈良好"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ellansé伊妍仕自上市后受到市场广泛关注及欢迎，医美机构订单踊跃，客户使用反馈良好",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "控股子公司珲达生物成立以来，已与多家国内外知名医药企业建立业务关系，海外业务占比超90%",
            "features": {
                "keywords": [
                    "珲达生物",
                    "业务关系",
                    "海外业务"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "国际合作"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "控股子公司珲达生物成立以来，已与多家国内外知名医药企业建立业务关系，海外业务占比超90%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "公司未研发及销售减肥药“悦小妖”产品",
            "features": {
                "keywords": [
                    "悦小妖",
                    "研发",
                    "销售"
                ],
                "sentiment_score": -0.1,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司未研发及销售减肥药“悦小妖”产品",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 5,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "治疗晚期非小细胞肺癌的迈华替尼正在开展3期临床试验，已完成3期临床受试者整体入组",
            "features": {
                "keywords": [
                    "迈华替尼",
                    "临床试验",
                    "晚期非小细胞肺癌"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "癌症治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "治疗晚期非小细胞肺癌的迈华替尼正在开展3期临床试验，已完成3期临床受试者整体入组",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "2020年度报告中列示存货中的原材料大部分为医药工业产品相关原材料",
            "features": {
                "keywords": [
                    "2020年度报告",
                    "存货",
                    "原材料"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2020年度报告中列示存货中的原材料大部分为医药工业产品相关原材料",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 4,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "TTP273目前在中国大陆、台湾地区开展2期临床试验",
            "features": {
                "keywords": [
                    "TTP273",
                    "临床试验",
                    "中国大陆",
                    "台湾地区"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "TTP273目前在中国大陆、台湾地区开展2期临床试验",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "公司没有研发及销售悦小妖产品",
            "features": {
                "keywords": [
                    "悦小妖",
                    "研发",
                    "销售"
                ],
                "sentiment_score": -0.1,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "公司没有研发及销售悦小妖产品",
                "Correlation": 6,
                "Sentiment": 3,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "治疗晚期非小细胞肺癌的迈华替尼正在开展3期临床试验 预计明年结束3期临床后开展上市申报工作",
            "features": {
                "keywords": [
                    "迈华替尼",
                    "临床试验",
                    "上市申报"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "癌症治疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "治疗晚期非小细胞肺癌的迈华替尼正在开展3期临床试验 预计明年结束3期临床后开展上市申报工作",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 10,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]